Alliqua Appoints Dr. Joseph Laudano as Vice President of Medical Affairs to Support the Market Expansion of Alliqua's SilverSeal

 Alliqua Appoints Dr. Joseph Laudano as Vice President of Medical Affairs to
   Support the Market Expansion of Alliqua's SilverSeal Products and Future
                             Clinical Development

PR Newswire

NEW YORK, Nov. 15, 2012

NEW YORK, Nov. 15, 2012 /PRNewswire/ -- Alliqua, Inc. (OTCQB:ALQA) ("Alliqua"
or the "Company"), an advanced biopharmaceutical company focused on the
development, manufacturing and distribution of proprietary transdermal wound
care and drug delivery technologies, today announced the appointment of Joseph
Laudano, Pharm.D. to the newly created position of Vice President, Medical
Affairs to support the market expansion of Alliqua's SilverSeal® products as
well as other future clinical developments. Dr. Laudano will lead the
development of a medical affairs team at Alliqua as the company now begins to
step up the marketing efforts for our proprietary 510K FDA approved
SilverSeal® hydrogels for wound care. He will also play a key role in the
planning and clinical development of our platform for transdermal drug
delivery

Commenting on the appointment, James Sapirstein, CEO of Alliqua stated, "We
are very pleased to have an industry veteran of such high caliber join our
team here at Alliqua. One of my primary near term goals as CEO of this
company is to put the right people in place that can deliver on the rich
potential of our proprietary technology as well as our future strategic
plans. Joe has extensive experience in some key therapeutic areas such as
dermatology and infectious diseases, which I believe align nicely with
Alliqua's future needs as we build this organization."

Dr. Laudano joins Alliqua with more than twenty five years of experience in
the pharmaceutical industry including four years as Senior Director of Medical
Affairs at Forest Research Institute, a subsidiary of Forest Labs, and twenty
years at Roche Laboratories. As Product Director at Roche he was responsible
for strategic/tactical planning, business development, marketing and
promotional activities for the diversified product portfolio which was
comprised of 16 different brands including Xenical, Rocephin and Accutane. He
was also part of the team that launched the Roche Dermatologics division at
Roche which was dedicated to the development and commercialization of systemic
and topical retinoids along with other compounds. He has extensive experience
in Medical Affairs and product development, particularly with antimicrobial
and dermatologic compounds, which will be critical to Alliqua as we move
forward with the science to support its transdermal drug delivery platform and
other future endeavors.

Commenting on his new position, Dr. Laudano added, "I am thrilled to become a
part of this exciting organization which I believe is entering a tremendous
new phase of growth. Having spent the better part of my career working with
infectious disease products, I am very impressed with the data which sets
SilverSeal apart from other hydrogel products. There are numerous
studiessupporting the efficacy of silver dressings in wound
management.Silver has broad spectrumactivity against bacteria including
MRSA, Pseudomonas, and otherantimicrobial-resistant bacteria. Based on this
activity andwith the increase of infections more resistant to antibiotic
treatments, dressings like our SilverSeal® hydrogels are perfectly positioned
to capitalize on the growing need in the medical marketplace for alternatives
for themanagement of open wounds in support ofantimicrobial stewardship
programs."

About Alliqua, Inc.

Alliqua, Inc. (ALQA) ("Alliqua") is a biopharmaceutical company focused on the
development, manufacturing and distribution of our proprietary transdermal
wound care and drug delivery technologies. Alliqua's leading technology
platform produces hydrogels, a three dimensional cross-linked network of water
soluble polymers capable of numerous chemical configurations. We currently
market our new line of 510K FDA approved hydrogel products for wound care
under our SilverSeal® brand. Due to our electron beam production process at
our 16,000 square foot GMP manufacturing facility, we can aggressively develop
and custom manufacture a wide variety of hydrogels. Our hydrogels can be
customized for various transdermal applications to address market
opportunities in the treatment of wounds such as diabetic ulcers, as well as
the delivery of numerous drugs or other agents for the pharmaceutical and
cosmetic industries. By using our drug delivery platform in combination with
certain drugs, pharmaceutical companies can increase patient compliance as
well as potentially extend the life of valuable drug patents. For additional
information, please visitwww.alliqua.com. To receive future press releases
via email, please visit:http://alliqua.com/index.php?page=investor-alerts.

Any statements contained in this press release regarding our ongoing research
and development and the results attained by us to-date have not been evaluated
by the Food and Drug Administration.

Legal Notice Regarding Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements
are generally identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend," or "project"
or the negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue reliance on
these forward-looking statements, as these statements are subject to numerous
factors and uncertainties outside of the our control that can make such
statements untrue, including, but not limited to, inadequate capital, adverse
economic conditions, intense competition, lack of meaningful research results,
entry of new competitors and products, adverse federal, state and local
government regulation, termination of contracts or agreements, technological
obsolescence of our products, technical problems with our research and
products, price increases for supplies and components, inability to carry out
research, development and commercialization plans, loss or retirement of key
executives and research scientists and other specific risks. We currently have
no commercial products intended to diagnose, treat, prevent or cure any
disease. The statements contained in this press release regarding our ongoing
research and development and the results attained by us to-date have not been
evaluated by the Food and Drug Administration. There can be no assurance that
further research and development, and/or whether clinical trial results, if
any, will validate and support the results of our preliminary research and
studies. Further, there can be no assurance that the necessary regulatory
approvals will be obtained or that we will be able to develop new products on
the basis of our technologies. In addition, other factors that could cause
actual results to differ materially are discussed in our Annual Report on Form
10-K filed with the SEC on March 29, 2012 and our most recent Form 10-Q
filings with the SEC. Investors and security holders are urged to read these
documents free of charge on the SEC's web site atwww.sec.gov. We undertake no
obligation to publicly update or revise our forward-looking statements as a
result of new information, future events or otherwise.

Contact:

Alliqua, Inc.
Steven Berger
646-218-1450



SOURCE Alliqua, Inc.

Website: http://www.alliqua.com
 
Press spacebar to pause and continue. Press esc to stop.